Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493491 | 0.74 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL3959438 | 0.74 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL5442144 | 0.74 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL9367939 | 0.71 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL8773823 | 0.71 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL6618701 | 0.71 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL6618819 | 0.71 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL4131831 | 0.71 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 | |
| SCHEMBL6171525 | 0.70 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12847565 | 0.69 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | SLC6A4 3271/4885SLC6A2 3670/4885SLC6A3 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.